Products
Pre-made Lumretuzumab benchmark antibody ( Whole mAb, anti-ERBB3/Erbb-3 therapeutic antibody, Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-328
Pre-Made Lumretuzumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lumretuzumab (INN; development code RG7116) is a humanized monoclonal antibody designed for the treatment of cancer.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-328-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Lumretuzumab biosimilar, Whole mAb, Anti-ERBB3/Erbb-3 Antibody: Anti-ErbB-3/FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB-3/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3 therapeutic antibody |
| INN Name | Lumretuzumab |
| Target | Erbb-3 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Discontinued |
| 100% SI Structure | 4leo:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Breast cancer;Solid tumours |
| Development Tech | GlycoMAb Technology |
<